A phase II trial of the combination of S-1 and paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with HER2-negative, stage II/III breast cancer. (March 2017) - Takahashi, Y.; Jinno, H.; Yoshikawa, M.; Matsumoto, A.; Ikeda, T.